Arpita Dutt | TalkMarkets | Page 1
Analyst at Zacks Research Pvt. Ltd.
Contributor's Links: Zacks Investment Research
Arpita has been an equity analyst at Zacks Investment Research since March, 2004.

All Contributions

Latest Posts
1 to 16 of 92 Posts
1 2 3 ... 6 >>>
3 Pharma And Biotech Stocks To Watch Out For In 2018
2017 turned out to be a pretty good year for pharma and biotech stocks with the Nasdaq Biotechnology index and the NYSE Arca Pharmaceutical index gaining 18.7% and 11.8%, respectively.
5 Of The Best-Performing Biotech Stocks Of 2017
2017 turned out to be a pretty good year for the biotech sector. The sector had been struggling due to the drug pricing controversy, mixed results, slower-than-expected new product launches, increasing competition and pipeline setbacks.
Pharma Stock Roundup: Roche, MNK Announce Acquisition Agreements, Regulatory Updates From Novartis
Key announcements in the pharma space this week include a couple of acquisition announcements and regulatory updates from Novartis.
3 Pharma & Biotech Pipeline Areas To Keep An Eye On In 2018
Although there are still a few days left for the year to end, 2017 has turned out to be pretty good for the pharma and biotech sector where FDA approvals are concerned.
4 Retail Stocks To Buy On Strong Industry Sales For November
The retail sector got a boost with the Commerce Department issuing a report last week on retail and food services sales for the month of November. With expectations high for a strong holiday season, here is a look at four retail stocks.
Pharma Stock Roundup: Teva Announces Major Job Cuts, Lilly Provides 2018 Outlook
Key announcements this week were Teva Pharmaceutical Industries Ltd.’s restructuring plan and Eli Lilly and Company’s 2018 outlook.
3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise
At the beginning of 2017, expectations were pretty high that the pharma and biotech sector would finally see lots of mergers and acquisitions (M&As). However, that did not happen.
Pfizer/Merck KGaA Drug Fails In Study, Teva CEO Announces Changes
While reports about tech giant Amazon meeting generic drugmakers made the rounds, companies like Pfizer and Teva Pharmaceutical Industries Ltd.’s were in the news with the former reporting late-stage data.
FDA Approves J&J, Glaxo HIV Drug, Roche Presents Data
Pipeline and regulatory updates were the focus this week with the FDA approving the first two-drug HIV treatment in the United States and the European Commission granting approval to Johnson & Johnson’s Tremfya.
5 Leisure & Travel Stocks To Benefit From Thanksgiving Vacation Plans
The travel and leisure industry is set to benefit thanks to several factors like a strong economy, higher incomes, higher consumer confidence and a strong labor market.
Pharma Stock Roundup: AstraZeneca's Q3 Earnings, Roche & Merck Drugs Get FDA Nod
Earnings remained in focus this week with companies like AstraZeneca reporting third-quarter results. Meanwhile, companies like Roche and Merck & Co., Inc. were in the news due to regulatory updates.
Pharma Stock Roundup: Pfizer, Teva's Q3 Earnings, Novartis Seeks New Indication For Kymriah
Major pharma companies like Pfizer, Teva Pharmaceutical Industries Limited, Sanofi, Allergan and Novo Nordisk reported third-quarter results last week.
Four Housing Stocks To Buy As New Home Sales Rebound
The biggest challenge for the housing market is low supply. Factors like rising lumber and land costs as well as tight labor supply and a shortage of land have been hitting inventory build-up.
5 Pharma & Biotech Stocks That Could Be Big Winners In Q3 Earnings
Pharma and biotech stocks started 2017 on a strong note with this part of the market remaining in favor as the year progresses. So far this year, the Nasdaq Biotechnology Index is up 25.6%.
Forget Teva, Buy These 5 Drug Stocks Instead
While Teva deals with these challenges, I have selected five drug companies that look well-positioned.
Pharma Stock Roundup: Mylan Up, Teva Down On Copaxone News, Lawmakers Question Allergan Deal
While Mylan and Teva were in the news related to the FDA approval of Mylan’s generic versions of Teva’s top-selling branded drug, Copaxone, Allergan is under fire for its agreement with the Saint Regis Mohawk Tribe for Restasis.
1 to 16 of 92 Posts
1 2 3 ... 6 >>>